Categories: News

Invitation to Vimian’s Interim Report for the Fourth Quarter of 2021

STOCKHOLM, SWEDEN / ACCESSWIRE / February 24, 2022 / Vimian Group (STO:VIMIAN)

Vimian Group AB will publish its Interim Report for the period of January-December 2021 on Thursday, 10 March 2022, at 07.45 (CET). An audiocast will be organised for investors, analysts and media, on the same day at 09.00 (CET).

CEO, Fredrik Ullman and CFO, Henrik Halvorsen from Vimian will present and comment on the report for the fourth quarter. The audiocast will be held in English and include a question-and-answer session.

To attend the telephone conference:
SE: +46 850 558 359
UK: +44 333 300 9262
US: +1 646 722 4904

To attend the webcast:
Link: https://tv.streamfabriken.com/vimian-group-q4-2021

Related presentation materials will be available at Vimian’s corporate website (https://vimian.com/investors/reports-and-presentations/) ahead of the audiocast.

For further information, please contact:

Maria Dahllöf Tullberg
Head of IR & Communications
maria.tullberg@vimian.com
+46 736 26 88 86

About Vimian

Vimian is a global, fast-growing group of innovation-driven companies with a shared passion for making a positive impact through improving animal health. Together, we put science, technology and our customers’ needs at the centre of everything we do to deliver effective solutions to veterinary professionals, labs and pet parents around the world. We bring together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. Our group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to our networks, expertise, infrastructure and capital to accelerate innovation and growth. We are as passionate about supporting leadership within our existing businesses, as we are about welcoming new partners to the Vimian family – together helping us make an even greater impact by improving animal health. Headquartered in Stockholm, Sweden, Vimian and our family of companies reach over 15,000 customers in +150 markets, employ more than 450 people and have a combined annual turnover of approximately EUR 140 million. FNCA Sweden AB is appointed the Company’s Certified Adviser, info@fnca.se, +46 (0) 8-528 00 399. For more information, please visit: www.vimian.com.

Attachments

Invitation to Vimian’s Interim Report for the fourth quarter of 2021

SOURCE: Vimian Group

View source version on accesswire.com:
https://www.accesswire.com/690249/Invitation-to-Vimians-Interim-Report-for-the-Fourth-Quarter-of-2021

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

8 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

11 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

11 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

11 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

11 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

11 hours ago